Start Date
April 30, 2024
Primary Completion Date
January 31, 2025
Study Completion Date
October 31, 2025
Pfizer-BioNTech Standard dose
"Standard Dose - (30ug in 0.3ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA)."
AstraZeneca Standard dose
"Standard Dose (5xE10vp in 0.5ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein"
Pfizer-BioNTech Fractional dose
"Fractional Dose - (15ug in 0.15ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA)."
AstraZeneca Fractional dose
"Fractional Dose (2.5E10vp in 0.25ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein"
Moderna Standard dose
Standard dose (50ug in 0.25ml)
Moderna Fractional dose
Fractional dose (20ug in 0.1ml)
Puskesmas Ciumbuleuit, Bandung
Puskesmas Dago, Bandung
Puskesmas Garuda, Bandung
Lead Sponsor
Universitas Padjadjaran
OTHER
Health Development Policy Agency, Ministry of Health Republic of Indonesia
UNKNOWN
Coalition for Epidemic Preparedness Innovations
OTHER
The Peter Doherty Institute for Infection and Immunity
OTHER
Indonesia University
OTHER
Murdoch Childrens Research Institute
OTHER